| Literature DB >> 34177810 |
Qian Li1, Dan Tian2, Jing Cen3, Lian Duan1, Weibo Xia1.
Abstract
Objective: Mutations in AQP2 (aquaporin-2) lead to rare congenital nephrogenic diabetes insipidus (NDI), which has been limitedly studied in Chinese population.Entities:
Keywords: Nephrogenic diabetes insipidus; aquaporin-2; mutation; vasopressin V2 receptor; water resorption
Mesh:
Substances:
Year: 2021 PMID: 34177810 PMCID: PMC8225504 DOI: 10.3389/fendo.2021.686818
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Mutation analysis of AQP2 in patients with NDI.
| No. | Type of mutation | Exon/Intron No. | Nucleotide change | Amino acid change | Amino acid location | Het/Hom | Inheritance | Family history | ACMG classification | Reported |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Frameshift | Exon1; Exon2 | c.127_128delCA; c.501_502 insC | p.Q43DfsTer63; p.V168RfsTer30 | TMD-2; | Compound Het | Maternal; Paternal | No | Pathogenic; | Yes; |
| TMD-5 | Pathogenic | Yes | ||||||||
| 2 | Missense | Exon4 | c.643G>A | p.G215S | TMD-6 | Hom | Maternal; Paternal | No | Pathogenic | Yes |
| 3 | Missense; Splicing | Exon2; Intron3 | c.494G>A; IVS3-1G>A | p.G165D; | TMD-5; N.A. | Compound Het | Maternal; De novo | No | Pathogenic; | No; |
| N.A. | Pathogenic | Yes | ||||||||
| 4 | Frameshift | Exon4 | c.759-783delGCGGCAGTCGGTGGAGCTGCACTCG | p.Q255RfsTer72 | ICT | Het | N.A. | No | Pathogenic | No |
| 5 | Splicing | Intron3 | IVS3-3delC | N.A | N.A | Het | Maternal | Yes | Pathogenic | No |
| 6 | Splicing | Intron3 | IVS3-3delC | N.A | N.A | Het | Paternal | Yes | Pathogenic | No |
| 7 | Missense; Missense | Exon1; Exon2 | c.298G>A; c.502G>A | p.G100R; p.V168M | TMD-3; TMD-5 | Compound Het | N.A. | No | Pathogenic; Pathogenic | Yes; |
| Yes |
TMD, transmembrane domain; ICT, intracellular C terminal; N.A., Not available.
Figure 1Pedigrees of the 7 families detected to carry pathogenic AQP2 mutations. The question mark indicates AQP2 mutation analysis of the individual was not performed.
Figure 2Distribution of AQP2 mutations detected in our patients with NDI. (A) Distribution of the nine mutations in AQP2 gene. (B) Schematic diagram of the primary structure of AQP2, showing the location of changed amino acid. The black rectangles indicate DNA coding sequence; the empty circles indicate amino acid of AQP2; the grey half-filled circles indicate amino acid alterations found in our study.
Clinical characteristics in patients with NDI.
| No. | Sex | Onset-age (months) | Age (years) | Polydipsia and polyuria | Intermittent fever | Short stature | Mental impairment |
|---|---|---|---|---|---|---|---|
| 1 | Male | 1 | 5 | + | + | + | – |
| 2 | Male | 4 | 8 | + | + | + | – |
| 3 | Male | 3 | 8 | + | – | – | – |
| 4 | Male | 3 | 12 | + | + | – | + |
| 5 | Male | 2 | 2 | + | + | + | – |
| 6 | Male | 6 | 22 | + | + | – | – |
| 7 | Male | 1 | 42 | + | + | – | – |
Y, years; M, months.
Biochemical and radiological characteristics in patients with NDI.
| No. | Age, years | The Urine Output, ml/kg/h | Urine SG (1.005-1.030) | Urine osmolality, mOsm/kgH2O | Serum osmolality, mOsm/kgH2O | Serum Na, mmol/L (135-145) | Serum Cr(E), μmol/L(18-62) | Serum UA, μmol/L(210-416) | Urological ultrasonography |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 5.3 | 1.002↓ | 50 | 350 | 154↑ | Normal | Normal | Normal |
| 2a | 8 | 11.3 | 1.002↓ | 157 | 307 | 143 | Normal | Normal | Normal |
| 3a | 8 | 6.5 | 1.002↓ | 63 | 304 | 149↑ | Normal | 504↑ | Normal |
| 4a | 12 | 6.9 | N.A. | 110 | N.A. | 142 | Normal | 459↑ | Mild hydronephrosis of the left kidney; mild dilation of the right ureter |
| 5 | 2 | 4.3 | <1.005↓ | 146 | 285 | 137 | Normal | Normal | N.A. |
| 6 | 22 | 12.8 | 1.000↓ | 65 | 290 | 140 | Normal | Normal | Hydronephrosis and dilation of the right kidney and ureter; irregularly thickened bladder wall |
| 7 | 42 | 13.9 | 1.001↓ | 60 | 308 | 148↑ | Normal | Normal | Hydronephrosis in the right kidney; dilation of the left ureter; irregularly thickened bladder wall |
means patients receiving drugs when evaluated.